(Q33697688)

28 July 2017

1 reference

title

Angiotensin II receptor antagonists and hypertension (English)

1 reference

28 July 2017

Mimran A

1

1 reference

28 July 2017

Ribstein J

series ordinal

2

1 reference

28 July 2017

DuCailar G

series ordinal

3

1 reference

28 July 2017

publication date

1 July 1999

1 reference

Clinical and Experimental Hypertension

28 July 2017

published in

1 reference

28 July 2017

volume

21

1 reference

28 July 2017

issue

5-6

1 reference

28 July 2017

page(s)

847-858

1 reference

The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Reversible dysgeusia attributed to losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Brief report: acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Reversible acute renal failure induced by losartan in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10641969909061014

10.3109/10641969909061014

21 January 2018

Identifiers

DOI

1 reference

release_x474arxdzvbebe5qdd5ikmedkm

28 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x474arxdzvbebe5qdd5ikmedkm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference